Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
出版年份 2021 全文链接
标题
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 3, Pages 398
出版商
MDPI AG
发表日期
2021-01-22
DOI
10.3390/cancers13030398
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
- (2020) Inju Cho et al. BMC CANCER
- Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
- (2020) Matias Autio et al. HAEMATOLOGICA
- Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
- (2020) Sirpa Leppä et al. Blood Advances
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program
- (2019) Ling Li et al. MODERN PATHOLOGY
- Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
- (2019) Ziju Y. Xu-Monette et al. Cancer Immunology Research
- PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype
- (2019) James Godfrey et al. BLOOD
- Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist
- (2019) Kevin W Ng et al. eLife
- The immune landscape and response to immune checkpoint blockade therapy in lymphoma
- (2019) Justin Kline et al. BLOOD
- Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer
- (2018) Zehong Chen et al. CANCER SCIENCE
- High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
- (2018) Yanyan Li et al. CANCER SCIENCE
- Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients
- (2018) Amro Mohamed Sedky El-Ghammaz et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
- (2018) Suvi-Katri Leivonen et al. HAEMATOLOGICA
- Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma
- (2018) Priscilla Brito da Silva et al. HEMATOLOGICAL ONCOLOGY
- Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
- (2018) S Ciavarella et al. ANNALS OF ONCOLOGY
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
- (2018) Kathleen M. Mahoney et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Identification and characterization of an alternative cancer-derived PD-L1 splice variant
- (2018) Nadia B. Hassounah et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
- (2017) D Rossille et al. LEUKEMIA
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- PD-1 expression on the surface of peripheral blood CD4+T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma
- (2016) Wei Zhang et al. Cancer Medicine
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
- (2015) Colm Keane et al. Lancet Haematology
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy
- (2013) Colm Keane et al. AMERICAN JOURNAL OF HEMATOLOGY
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
- (2013) SR Greisen et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
- (2011) Mi-Young Song et al. JOURNAL OF IMMUNOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started